The Miedel Lab uses human biomimetic liver microphysiology systems (MPS) to model both normal and disease-state liver physiology and the main areas of focus are in:
(1) coupling the use of quantitative systems pharmacology (QSP) and liver MPS as a precision medicine platform to identify novel biomarkers and targets for drug discovery for metabolic dysfunction-associated steatotic liver disease (MASLD).
(2) 3D bioprinting of complex liver models.
(3) using MPS to examine the impact of the liver tumor microenvironment on the progression of different cancer types.
My research uses human biomimetic liver microphysiological systems (MPS) to model both normal and disease-state liver physiology. My focus is on implementing the coupled use of liver MPS with quantitative systems pharmacology (QSP) as an integrated platform for identifying mechanisms and biomarkers of MASLD/MASH disease progression and as a drug testing platform to inform precision medicine therapeutic strategies for drug discovery that can be applied to select patient cohorts using patient-derived primary and/or iPSC liver cells. Using this approach, we have identified key differences in MASLD progression and response to therapeutics in liver MPS constructed with patient cells harboring the PNPLA3 I148M mutation, a key known genetic variant known to be associated with more severe MASLD phenotypes. I also have interest in utilizing liver MPS to examine the impact of the liver tumor microenvironment on metastatic phenotypes that are associated with the progression of different cancer types (metastatic melanoma and breast cancer) as well as using 3D bioprinting technology to generate higher throughput liver MPS for larger drug screening efforts.
The Miedel Lab uses human biomimetic liver microphysiology systems (MPS) to model both normal and disease-state liver physiology and the main areas of focus are in:
(1) coupling the use of quantitative systems pharmacology (QSP) and liver MPS as a precision medicine platform to identify novel biomarkers and targets for drug discovery for metabolic dysfunction-associated steatotic liver disease (MASLD).
(2) 3D bioprinting of complex liver models.
(3) using MPS to examine the impact of the liver tumor microenvironment on the progression of different cancer types.